Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00896727 · ClinicalTrials.gov registry record
S9313A Protein Expression Analysis of Breast Cancer Tissue Microarrays From Clinical Trial SWOG-9313
A clinical trial, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- 2,100
- Enrollment target
NCT00896727: Completed study, sponsored by SWOG Cancer Research Network.
NCT00896727 is a clinical trial that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 2,100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00896727 has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- 2,100 participants
- Enrollment target
Study Summary
RATIONALE: Studying the proteins expressed in tumor tissue samples in the laboratory from patients with cancer may help doctors learn more about biomarkers related to cancer. It may also help doctors predict how patients respond to treatment. PURPOSE: This laboratory study is looking at protein expression in predicting response to treatment using tumor tissue samples from women with stage I, stage II, or stage IIIA breast cancer treated on clinical trial SWOG-9313.
Primary Outcome
at baseline
Interventions
- GENETIC gene expression analysis
- GENETIC protein expression analysis
- OTHER laboratory biomarker analysis
- OTHER fluorescent antibody technique
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,100 participants |
| Start Date | 2006-07-17 |
| Est. Completion | 2009-04-02 |
What the finished NCT00896727 record still lists
NCT00896727 is an observational study that tracks outcomes without assigning an intervention. Its 2,100 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 4 interventions - of which gene expression analysis is the first listed.
NCT00896727 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00896727 about?
NCT00896727 is a clinical study titled "S9313A Protein Expression Analysis of Breast Cancer Tissue Microarrays From Clinical Trial SWOG-9313". RATIONALE: Studying the proteins expressed in tumor tissue samples in the laboratory from patients with cancer may help doctors learn more about biomarkers related to cancer. It may also help doctors predict how patients respond to treatment. PURPOSE: This laboratory study is looking at protein exp...
What is the current status of trial NCT00896727?
This trial is currently completed. The enrollment target is 2,100 participants. The study started on 2006-07-17. Estimated completion is 2009-04-02.
What interventions are being tested in trial NCT00896727?
The interventions under investigation include: gene expression analysis (GENETIC), protein expression analysis (GENETIC), laboratory biomarker analysis (OTHER), fluorescent antibody technique (OTHER).
Who is sponsoring clinical trial NCT00896727?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04649242 · 2,100 participants · Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- NCT05206331 · 2,100 participants · Phase 4
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
- NCT05270499 · 2,100 participants
Aveir VR Real-World Evidence Post-Approval Study
- NCT06324981 · 2,100 participants · NA
Using AI Text Messaging to Improve AHA's Life's Essential 8 Health Behaviors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI